- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07389525
Immune Checkpoint Remmer (ICR)-Geneesmiddel-Geneesmiddel Interactie (GGI)-studie
Beoordeling van geneesmiddelinteracties tussen immuuncheckpointremmers en cytochroom P450 substraten: Immuuncheckpointremmer (ICI)-geneesmiddelinteractie (DDI) studie
Immune checkpoint inhibitors (ICIs) (also called "immunotherapy") are an effective family of anti-cancer drugs, but they can cause serious side effects. Some evidence suggests these side effects might happen because ICIs interact with other drugs that you may already be taking, making those drugs work differently, or causing more side effects. The purpose of this study is to see whether ICIs impact how the liver processes other drugs. To do this, participants will be given a probe cocktail of 7 different FDA-approved drugs that are processed in different ways in the liver.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Findings suggest that adverse events during checkpoint inhibitor therapy may, in part, be caused by drug-drug interactions that increase the risk of adverse events with co-administered medications. Identifying these novel drug-drug interactions will likely inform clinical strategies to reduce adverse events during checkpoint inhibitor therapy and enhance their clinical benefits.
This current research aims to systematically explore the impact of ICIs on CYP/transporter function and the associated risks for adverse events, thereby informing clinical strategies to mitigate these risks and optimize the therapeutic benefits of checkpoint inhibitors. By employing a rigorous crossover drug-drug interaction design, this study seeks to enhance understanding of drug interactions during ICI therapy, ultimately improving patient outcomes in oncology.
The long-term goal of this research is to find ways to manage adverse events that occur during treatment with ICIs. The research has two main aims:
- To understand how ICI therapy affects the metabolism of certain drugs named CYP/transporter probe drugs and to also understand the risk of side effects from commonly prescribed drugs that are affected by these enzymes and transporters in cancer patients.
- To examine the relationship between levels of pro-inflammatory cytokines (signaling molecules involved in inflammation) and how well these probe drugs are metabolized before and during ICI therapy.
A two-phase clinical study will be conducted to achieve these aims: patients will be given seven different probe drugs that interact with key enzymes and transporters (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A, BCRP, and SLCO1B1) both before they start ICI treatment and after they have begun therapy.
Adverse events will be assessed by looking at how changes in the function of these enzymes and transporters affect the metabolism of drugs that cancer patients commonly use. Special computer models, known as physiologically-based pharmacokinetic (PBPK) models, will be used to simulate how these drugs behave in the body and predict potential serious adverse events.
Studietype
Inschrijving (Geschat)
Fase
- Vroege fase 1
Contacten en locaties
Studiecontact
- Naam: Ross Robinson
- Telefoonnummer: 317-381-1426
- E-mail: rossrobi@iu.edu
Studie Locaties
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center
-
Contact:
- Ross Robinson
- Telefoonnummer: 317-381-1426
- E-mail: rossrobi@iu.edu
-
Hoofdonderzoeker:
- Tyler Shugg, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- ≥ 18 years old at the time of informed consent
- Diagnosed with cancer AND initiating therapy with single agent or combination therapy that includes an immune checkpoint inhibitor (e.g., atezolizumab, cemiplimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatlimab, tremelimumab)
- Ability to provide written informed consent and HIPAA authorization
Exclusion Criteria:
-
Actively pregnant or breastfeeding
-
Body weight less than 50 kg or a BMI >35
-
Low baseline hemoglobin, defined as <10 g/dL
- Note: if a prospective patient's hemoglobin returns to the normal range, they can be re-screened for trial inclusion)
-
Past medical history of chronic liver disease, signs and symptom of liver disease (e.g., jaundice, ascites), or aspartate aminotransferase >96 U/L, alanine aminotransferase > 80 IU/L, alkaline phosphatase >260 U/L, or total bilirubin > 2.6 mg/dL
- Note: if a prospective patient's liver function tests return to the normal ranges, they can be re-screened for trial inclusion)
-
Past medical history of chronic kidney disease, signs and symptom of kidney disease (e.g., decreased urine output, swelling in feet and ankles), or estimated glomerular filtration rate <45 mL/minute/1.73 m2 BSA
- Note: if a prospective patient's kidney function returns to the normal range, they can be re-screened for trial inclusion)
-
Poor performance status that makes it unlikely the patient will complete 3 cycles of immune checkpoint inhibitor (at the treating oncologist's discretion)
-
Diagnosis or past medical history of autoimmune disorder, including systemic lupus erythematosus, Crohn's disease, Sjogren's syndrome, multiple sclerosis, type 1 diabetes mellitus, Behcet's disease, and ankylosing spondylitis
-
History of intolerance, allergic reaction, or hypersensitivity to any of the study drugs (tizanidine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, rosuvastatin)
-
Current infection requiring medical treatment (note: if a prospective patient's infection resolves, they can be re-screened for trial inclusion)
-
Concomitant treatment with systemic immunosuppressant drugs (see Appendix 3 for list)
- Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1
-
Concomitant treatment with a CYP/transporter probe cocktail drug or strong inhibitors, inducers, or agents that affect the pharmacokinetics of the relevant CYP enzymes or drug transporters (see Appendix 4 for list)
- Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1
-
Are unwilling/unable to avoid drugs of abuse, tobacco products or marijuana, or consuming more than 2 alcoholic drinks per day during the study
-
Inability to take oral medication
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Cohort 1
CYP enzyme/drug transporter probe substrates administered at two study visits: one before initiation of ICI therapy and one while on therapy. |
Low dose of a cocktail of probe substrates for eight major CYP enzymes/drug transporters. |
|
Experimenteel: Cohort 2
CYP enzyme/drug transporter probe substrates administered at one study visit: during ICI therapy. |
Low dose of a cocktail of probe substrates for eight major CYP enzymes/drug transporters. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Verandering in plasmaconcentraties door geneesmiddelblootstelling tijdens ICI-therapie
Tijdsspanne: baseline (voor aanvang van ICI-therapie) tot en met dag 84
|
baseline (voor aanvang van ICI-therapie) tot en met dag 84
|
|
Toxiciteitsconcentraties voor CYP/transporter-substraatgeneesmiddelen in plasma
Tijdsspanne: baseline (dag voor start Cyclus 1) tot dag 84
|
baseline (dag voor start Cyclus 1) tot dag 84
|
|
Associaties tussen concentraties van pro-inflammatoire cytokines en concentraties van CYP/transporter probes in plasma
Tijdsspanne: baseline (dag voor start Cyclus 1) tot dag 84
|
baseline (dag voor start Cyclus 1) tot dag 84
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Assess associations between T cells populations and CYP/transporter probe drug concentrations
Tijdsspanne: baseline (day before Cycle 1 start) up to day 84
|
Peripheral blood mononuclear cells (PBMCs) |
baseline (day before Cycle 1 start) up to day 84
|
|
Concentrations of endogenous biomarkers
Tijdsspanne: baseline (day before Cycle 1 start) up to day 84
|
Plasma or urine |
baseline (day before Cycle 1 start) up to day 84
|
|
CYP/transporter endogenous biomarker concentrations
Tijdsspanne: baseline (day before Cycle 1 start) up to day 84
|
Plasma or urine correlated with plasma concentrations of pro-inflammatory cytokines |
baseline (day before Cycle 1 start) up to day 84
|
|
Correlation of concentration of population of activated T cells and CYP/transporter endogenous biomarkers
Tijdsspanne: baseline (day before Cycle 1 start) up to day 84
|
Plasma or urine |
baseline (day before Cycle 1 start) up to day 84
|
|
CYP/transporter substrate-related adverse events and immune related (ir) adverse events
Tijdsspanne: Baseline (before starting ICI cycle 1) and study visit 2 (up to day 84)
|
assessed through surveys given to participants |
Baseline (before starting ICI cycle 1) and study visit 2 (up to day 84)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Tyler Shugg, MD, IUSCCC
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Neoplasmata per site
- Neoplasmata
- Mannelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Neoplasmata per histologisch type
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Huidziektes
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Neuro-endocriene tumoren
- Neoplasmata, bindweefsel en zacht weefsel
- Nevi en melanomen
- Huidneoplasmata
- Huid- en bindweefselaandoeningen
- Gastro-intestinale neoplasmata
- Melanoma
- Sarcoom
- Urogenitale neoplasmata
Andere studie-ID-nummers
- PHARM-IUSCCC-0938
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .